In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies Commercial Executive Changes

Execs On The Move: May 2022

  • Data

Executive Summary

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

You may also be interested in...



Minute Insight: SonALAsense MR-Guided Ultrasound Drug-Device Combo Trials Get Green Light

SonALAsense has received Safe to Proceed letters from the FDA to begin trials of its ultrasound-activated cancer killing drug.

Snapshot: June Highlights

A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.

Paige Secures Eighth CE Mark For Cancer Identification AI

The Memorial Sloan Kettering spin-out has received CE-IVD and UKCA marks for its artificial intelligence software designed to identify HER2 expression in biopsies.

Table

View full table

Topics

Tags:
Companies Commercial Executive Changes
Latest News

Funding The Future: Accelerating The Long Walk To Innovation

Micro-Dosing Gene Therapy: A Recipe For Success?

Snapshot: June Highlights

Pharma Spreads Its Bets On Multiple Modalities In Advanced Products

UsernamePublicRestriction

Register

IV125106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By